Cost-effectiveness of intravenous vedolizumab vs subcutaneous adalimumab for moderately to severely active ulcerative colitis

BACKGROUND: The efficacy of intravenous (IV) vedolizumab vs subcutaneous (SC) adalimumab for the treatment of moderately to severely active ulcerative colitis (UC) was assessed in the VARSITY clinical trial, which demonstrated for the first time in a head-to-head clinical trial setting the superiori...

Descripción completa

Detalles Bibliográficos
Autores principales: Schultz, Bob G, Diakite, Ibrahim, Carter, John A, Snedecor, Sonya J, Turpin, Robin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10390957/
https://www.ncbi.nlm.nih.gov/pubmed/34714104
http://dx.doi.org/10.18553/jmcp.2021.27.11.1592

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10390957/
https://www.ncbi.nlm.nih.gov/pubmed/34714104
http://dx.doi.org/10.18553/jmcp.2021.27.11.1592

Ejemplares similares